Among insulin sensitizers, metformin has recently acquired a central role in the treatment of T2DM and other disorders associated with insulin resistance, such as polycystic ovary syndrome (PCOS), and both experimental and clinical studies have recently supported the use of metformin as a useful adjunct in NAFLD patients. This evidence concerns the gene INS and polycystic ovary syndrome.